

Supplementary Table 2. Summary statistics of SL, WASO, number of enquiries, and TST at baseline and end of treatment (intent-to-treat population; observed case)

Sleep characteristic (min)	Time point	Esmirtzapine 1.5 mg (n=128)		Esmirtzapine 3.0 mg (n=129)	
		Mean (SD)	Median (range)	Mean (SD)	Median (range)
Sleep duration					
TST	n	127	127	128	128
	Baseline	294.0 (71.0)	300.0 (150.0 to 666.0)	293.5 (67.3)	300.0 (0.0 to 436.0)
	n	124	124	129	129
	End of treatment	381.0 (82.5)	390.0 (120.0 to 510.0)	380.4 (99.1)	390.0 (6.0 to 660.0)
Sleep maintenance					
WASO	n	127	127	128	128
	Baseline	109.4 (86.4)	90.0 (0.0 to 660.0)	102.4 (71.0)	90.0 (13.0 to 540.0)
	n	124	124	129	129
	End of treatment	47.5 (53.9)	30.0 (0.0 to 360.0)	52.1 (67.4)	25.0 (0.0 to 360.0)
Sleep induction					
SL	n	127	127	127	128
	Baseline	88.6 (72.5)	60.0 (9.0 to 480.0)	91.4 (77.7)	70.0 (4.0 to 36.0)
	n	124	124	129	129
	End of treatment	60.8 (81.4)	30.0 (5.0 to 445.0)	69.3 (85.7)	30.0 (3.0 to 450.0)

SD: standard deviation, SL: sleep latency, TST: total sleep time, WASO: wake time after sleep onset